Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalcetrapib in ACS with AA Genotype
NCT02525939Phase 3Completed
- Sponsor
- DalCor Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 32
01
Overview
A Phase 3 trial of dalcetrapib in acute coronary syndrome (ACS), sponsored by DalCor Pharmaceuticals. Started Apr 2016; status: completed.
02
Drugs
dalcetrapib
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02525939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02525939.